HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bronchodilator reversibility, airway eosinophilia and anti-inflammatory effects of inhaled fluticasone in COPD are not related.

AbstractBACKGROUND AND OBJECTIVE:
Bronchodilator reversibility (BDR) is common in smoking-related COPD, but the airway pathology underlying this has not been described. In particular, it is not known whether BDR is associated with underlying airway eosinophilia and whether BDR is predictive of a better response to inhaled corticosteroid (ICS) treatment.
METHODS:
A double-blind, placebo-controlled, randomized 2:1 study of fluticasone propionate (FP), 500 microg twice daily versus placebo over 6 months was performed in subjects with mild to moderate COPD. Subjects with a clinical history of asthma were excluded, but not on BDR criteria alone. Induced sputum, BAL and endobronchial biopsies (EBB) were performed in 36 subjects at baseline, and 30 of these provided a second full set of samples (FP, n = 19; placebo, n = 11).
RESULTS:
Baseline BDR was not related to airway eosinophilia and did not predict response to ICS. Post-bronchodilator FEV(1) increased in the FP group compared with the placebo group (P = 0.05), and there were within-treatment group reductions in total symptom scores with FP (P < 0.05). Compared with placebo, FP reduced macrophage numbers but increased neutrophil numbers in EBB (P = 0.01 and P = 0.003, respectively). BAL neutrophil and epithelial cell numbers were also reduced with FP (P = 0.03 for both). There were within-treatment group reductions in the numbers of EBB mast cells and CD8+ve lymphocytes with FP (P = 0.007).
CONCLUSIONS:
BDR was not related to any particular inflammatory phenotype or any clinical or anti-inflammatory response to ICS in these subjects with mild to moderate COPD.
AuthorsDavid W Reid, Yudong Wen, David P Johns, Trevor J Williams, Chris Ward, E Haydn Walters
JournalRespirology (Carlton, Vic.) (Respirology) Vol. 13 Issue 6 Pg. 799-809 (Nov 2008) ISSN: 1440-1843 [Electronic] Australia
PMID18811878 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Androstadienes
  • Anti-Inflammatory Agents
  • Fluticasone
Topics
  • Administration, Inhalation
  • Aged
  • Androstadienes (pharmacology, therapeutic use)
  • Anti-Inflammatory Agents (pharmacology, therapeutic use)
  • Cell Count
  • Cross-Sectional Studies
  • Double-Blind Method
  • Eosinophilia (drug therapy)
  • Female
  • Fluticasone
  • Humans
  • Male
  • Middle Aged
  • Pulmonary Disease, Chronic Obstructive (drug therapy)
  • Quality of Life
  • Respiratory Function Tests
  • Respiratory Mucosa (cytology, drug effects)
  • Sputum (cytology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: